CAS
NO. |
30516-87-1
(Base) 106060-86-0 (sodium salt) |
|
EINECS
NO. |
|
FORMULA |
C10H13N5O4 |
MOL
WT. |
267.24 |
H.S.
CODE
|
|
TOXICITY
|
|
SMILES |
|
SYNONYMS |
3-Azido-3-deoxythymidine;
AZT; ZDV; ZVD; |
3'-deoxy-3'-azidothymidine; azidodeoxythymidine;
Azidothymidine; 3'-Azidothymidine; 3'-Azido-3'-deoxythymidine; |
CLASSIFICATION
|
|
PHYSICAL
AND CHEMICAL PROPERTIES
|
PHYSICAL
STATE |
White to
off-white Crystals |
MELTING
POINT |
110
- 115 C |
BOILING
POINT |
|
SPECIFIC
GRAVITY |
|
SOLUBILITY
IN WATER |
|
pH |
|
VAPOR
DENSITY |
|
AUTOIGNITION |
|
NFPA
RATINGS |
Health:
1 Flammability: 1 Reactivity: 0 |
REFRACTIVE
INDEX
|
|
FLASH
POINT |
|
STABILITY |
Stable
under ordinary conditions |
GENERAL
DESCRIPTION & APPLICATIONS
|
Zidovudine is a thymidine analogue in which the 3'-hydroxy (-OH) group is
replaced by an azido (-N3) group. It is used in the management of human
immunodeficiency virus. It is an antiretroviral agent that inhibits replication
of some retroviruses. It is converted into the active metabolite zidovudine
5'-triphosphate which inhibits the activity of the HIV (human immunodeficiency
virus) reverse transcriptase within cells. The viral DNA growth is terminated
due to the lack of 3'-OH group which prevents the formation of the essential for
DNA chain elongation (5' to 3' phosphodiester). Zalcitabine
(2',3'-dideoxycytidine), a 2'-deoxycytidine analogue which does not have -OH
group both at 2' and at 3' position, is an antiretroviral agent used in
combination with zidovudine. Zalcitabine is converted into the active metabolite
dideoxycytidine 5'-triphosphate that inhibits the action of reverse
transcriptase. 3'-Azido-3'-deoxythymidine
and 2',3'-dideoxycytidine are used in the study for antiviral and anticancer
researches. Protease inhibitors
are the second class of antiretroviral drugs for the treatment of HIV.
Aantiretroviral agents
- Non-nucleoside reverse transcriptase inhibitors
- Delavirdine
[CAS #: 136817-59-9]
- Delavirdine mesylate [CAS
#: 147221-93-0]
- Efavirenz
[CAS #: 154598-52-4]
- Nevirapine
[CAS #: 129618-40-2]
- Nucleoside/Nucleotide reverse transcriptase
inhibitors
- Abacavir
[CAS #: 136470-78-5]
- Abacavir succinate
[CAS #: 168146-84-7]
- Abacavir sulfate
[CAS #: 188062-50-2]
- Adefovir [CAS
#: 106941-25-7]
- Adefovir dipivoxil
[CAS #: 142340-99-6]
- Combivir
(Lamivudine/Zidovudine mixture) [CAS #: 165456-81-5]
- Didanosine
[CAS #: 69655-05-6]
- Emtricitabine
[CAS #: 143491-57-0]
- Lamivudine
[CAS #: 134678-17-4]
- Lamivudine sulfoxide
[CAS #: 160552-55-6]
- Pradefovir mesylate [CAS
#: 625095-61-6]
- Stampidine
[CAS #: 217178-62-6]
- Stavudine [CAS
#: 3056-17-5]
- Tenofovir [CAS
#: 147127-20-6]
- Tenofovir disoproxil
[CAS #: 201341-05-1]
- Tenofovir Disoproxil
Fumarate [CAS #: 202138-50-9]
- Trizivir
(Abacavir sulfate/Lamivudine/Zidovudine mixture) [CAS #: 364057-50-1]
- Zalcitabine
[CAS #: 7481-89-2]
- Zidovudine
[CAS #: 30516-87-1]
- Zidovudine sodium
salt [CAS #: 106060-86-0]
- Protease inhibitors
- Amprenavir [CAS
#: 161814-49-9]
- Atazanavir
[CAS #: 198904-31-3]
- Atazanavir sulfate
[CAS #: 229975-97-7]
- Fosamprenavir
[CAS #: 226700-79-4]
- Fosamprenavir calcium
[CAS #: 226700-81-8]
- Fosamprenavir sodium
[CAS #: 226700-80-7]
- Indinavir
[CAS #: 150378-17-9]
- Indinavir hydrate
[CAS #: 180683-37-8]
- Indinavir Sulfate
[CAS #: 157810-81-6]
- Kaletra
(Lopinavir/Ritonavir mixture)
[CAS #: 369372-47-4]
- Lopinavir
[CAS #: 192725-17-0
- Nelfinavir [CAS
#: 159989-64-7]
- Nelfinavir mesylate
[CAS #: 159989-65-8]
- Ritonavir
[CAS #: 155213-67-5]
- Saquinavir
[CAS #: 127779-20-8]
- Saquinavir mesylate
[CAS #: 149845-06-7]
- Tipranavir
[CAS #: 174484-41-4]
- Tipranavir disodium
[CAS #: 191150-83-1]
|
SALES
SPECIFICATION |
APPEARANCE
|
White to
off-white Crystals |
IDENTIFICATION
|
passes
test A,B
|
ASSAY |
99.0%
min
|
OPTICAL
ROTATION |
+46°
~ +48° (C=0.5 in water)
|
WATER
|
0.5%
max
|
HEAVY
METALS
|
20ppm
max
|
LOSS
ON DRYING |
0.5%
max
|
TRANSPORTATION |
PACKING |
|
HAZARD
CLASS |
|
UN
NO. |
|
OTHER
INFORMATION |
Hazard Symbols: XN, Risk Phrases: 40, Safety Phrases: 36/37/39-45 OTHER
INFORMATION
|